According to the latest report by IMARC Group, titled “Ovarian Cancer Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” offers a comprehensive analysis of the industry, which comprises insights on the global ovarian cancer market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
The global ovarian cancer market size reached US$ 1.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach a value of US$ 3.7 Billion by 2028, exhibiting a growth rate (CAGR) of 1.56% during 2023-2028.
Ovarian cancer is caused by the abnormal growth of cells in the ovaries that begin to multiply and grow uncontrollably from the outer tissue lining or fallopian tubes due to mutagenic changes in the deoxyribonucleic acid (DNA).
Some commonly known ovarian cancers are epithelial ovarian carcinomas, germ cell tumors, stromal cell tumors, and ovarian sarcoma. They are treated with chemotherapy, surgery, immunotherapy, radiation, and targeted therapies that help kill cancer cells and relieve signs and symptoms. These therapeutics are performed by medical practitioners after determining multiple factors, such as the spread of the tumor, the individual’s general health, and the size and type of ovarian cancer. As a result, ovarian cancer treatment is widely adopted across hospitals and specialty centers.
Request For Sample Report https://www.imarcgroup.com/ovarian-cancer-market/requestsample
What Are The Key Factors Driving In The Ovarian Cancer Market ?
The market is primarily driven by the increasing prevalence of ovarian cancer. This can be attributed to the family history of ovarian cancer, inhabitation of gene mutation (BRCA1 or BRCA2), lynch syndrome amongst the female geriatric population, obesity, and endometriosis. In addition, the widespread adoption of combination therapies in the healthcare industry to prevent drug resistance and increase treatment efficacy is contributing to market growth.
Moreover, various initiatives undertaken by non-governmental organizations (NGOs) to sensitize consumers concerning the symptoms, treatments, and benefits of early ovarian cancer diagnosis represent another major growth-inducing factor.
Besides this, the market is further propelled by the extensive investment in cancer research worldwide. Moreover, with the ongoing patent expiration of branded medications, pharmaceutical companies are introducing novel recombinant drugs. This, coupled with the extensive research and development (R&D) activities to produce efficient therapeutic interventions and strategic collaborations amongst key players, is creating a positive market outlook across the globe.
Who Are The Key Players/Companies In The Global Liquid Packaging Market?
AbbVie Inc., Amneal Pharmaceuticals Inc., AstraZeneca plc, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Hikma Pharmaceuticals PLC, Lupin Limited, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.
The report has been segmented the market into following categories:
Breakup by Type:
- Epithelial Ovarian Cancer
- Germ Cell Ovarian Cancer
- Stromal Cell Ovarian Cancer
Breakup by Treatment Type:
- Targeted Therapy
Breakup by End User:
- Speciality Centre
- Asia Pacific
- North America
- Middle East and Africa
- Latin America
On the geographical front, Asia Pacific enjoys the leading position in the market. This can be attributed to the rising establishment of international companies in the region, on account of low manufacturing costs and cheap labor.
Ask An Analyst: https://www.imarcgroup.com/request?type=report&id=6407&flag=C
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 |
Africa and Europe :- +44-702-409-7331 |
Asia: +91-120-433-0800, +91-120-433-0800